Avecho Biotechnology (ASX: AVE): Breakout Above Long-Term Resistance Puts Trend Sustainability in Focus
Jun 26, 2026
Proactive Equities Team
Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.